Compare IDEXX Laboratories, Inc. (IDXX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nvidia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $573.66 (market cap $46.22B), while Nvidia Corp trades at $223.71 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 114× IDEXX Laboratories, Inc.'s market cap, and Nvidia Corp pays a 0.46% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NVDA | |
|---|---|---|
Market Cap | $46.22B | $5.27T |
Sector | Health | Technology |
52-Week High | $766.68 | $235.75 |
52-Week Low | $526.44 | $165.17 |
Enterprise Value | $47.12B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
NVIDIA (NVDA) trades at $223.09, up 2.54% today, with strong technical momentum as the price approaches resistance near $224. The company demonstrates exceptional fundamental strength with 55.84% net profit margins and 114.29% ROE for 2025, supported by consistent earnings beats. Recent news highlights AI leadership driving revenue growth acceleration, though some articles caution about growth sustainability given the stock's massive run-up.
Outlook remains positive with Wall Street consensus target of $325.86 implying 46% upside, though risks include peak AI spending concerns and increased competition. The stock presents a compelling growth opportunity but requires careful risk management given elevated valuations and technical overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
